Related Experiment Video
Updated: Aug 11, 2026
04:10
Robotic-assisted Bronchoscopy Combined with Multimodal Imaging for Targeted Lung Cryobiopsies
Published on: July 19, 2024
An integrated clinical approach to diffuse cystic lung diseases
Sergio Harari1, Giuseppe Paciocco
1Unità Operativa di Pneumologia, UTIR Servizio di Fisiopatologia Respiratoria e Laboratorio di Emodinamica Polmonare, Ospedale San Giuseppe, AFAR, Milano, Italy. sharari@fatebenefratelli.it
Summary
Lymphangioleiomyomatosis and Langerhans cell Histiocytosis are rare lung diseases with similar symptoms. This review highlights key differences to aid in differential diagnosis for better patient outcomes.
Area of Science:
- Pulmonology
- Rare Diseases
- Oncology
Background:
- Lymphangioleiomyomatosis (LAM) and Langerhans cell Histiocytosis (LCH) are distinct pulmonary diseases of unknown origin.
- Both conditions are rare and can present with overlapping radiological and clinical features, including lung nodules, cysts, dyspnea, hemoptysis, and pneumothorax.
- The similar presentation often complicates differential diagnosis, potentially delaying appropriate management.
Purpose of the Study:
- To differentiate between LAM and LCH in the context of pulmonary involvement.
- To provide clinicians with key distinguishing factors for accurate diagnosis.
- To improve understanding of the epidemiology, pathogenesis, and prognosis of these rare lung diseases.
Main Methods:
- Comparative review of existing literature on LAM and LCH.
- Analysis of epidemiological data, pathogenetic mechanisms, and clinical outcomes.
- Focus on radiological and clinical presentations to identify differentiating characteristics.
Main Results:
- LAM and LCH exhibit distinct epidemiological profiles and underlying pathogenetic mechanisms.
- While radiological patterns (nodules, cysts) and symptoms (dyspnea, hemoptysis) can overlap, subtle differences exist.
- Prognostic trajectories and treatment responses vary significantly between the two diseases.
Conclusions:
- Despite overlapping presentations, LAM and LCH are fundamentally different diseases.
- Understanding differences in epidemiology, pathogenesis, and prognosis is crucial for accurate differential diagnosis.
- This review offers guidance to clinicians managing patients with these rare and severe pulmonary conditions.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment